William S. Simon - 01 Dec 2025 Form 4 Insider Report for Hanesbrands Inc. (HBI)

Reporting relationship: Director
Issuer ticker: HBI
Reported as of: 01 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 01 Dec 2025, 10:03:07 UTC
Prior SEC filing: 19 Sep 2025
Next SEC filing: 25 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Carlyle Cromer, Attorney-in-Fact

Key filing fact

William S. Simon filed Form 4 for Hanesbrands Inc. (HBI) on 01 Dec 2025.

Key facts

This page summarizes William S. Simon's Form 4 filing for Hanesbrands Inc. (HBI).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 Dec 2025, 10:03.

Change

Previous filing in this sequence was filed on 19 Sep 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001349347 Primary reporting owner

Simon William S

Relationship: Director
Address: 101 NORTH CHERRY STREET, WINSTON-SALEM
Signature: /s/ Carlyle Cromer, Attorney-in-Fact
Signature date: 01 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

HBI transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -59,773
Change %: -76%
Price
Shares after: 18,630
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F1

HBI transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -18,630
Change %: -100%
Price
Shares after: 0
Date: 01 Dec 2025
Ownership: Direct
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

William S. Simon is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

Disposed of pursuant to the Agreement and Plan of Merger, dated as of August 13, 2025 (the "Merger Agreement"), by and among the Issuer, Gildan Activewear Inc. ("Gildan"), Galaxy Merger Sub 2, Inc., a direct wholly owned subsidiary of Gildan ("Second Gildan Merger Sub"), Galaxy Merger Sub 1, Inc., a direct wholly owned subsidiary of Second Gildan Merger Sub ("First Gildan Merger Sub"), Helios Holdco, Inc., a direct wholly owned subsidiary of the Issuer ("Hanesbrands Holdco"), and Helios Merger Sub, Inc., a direct wholly owned subsidiary of Hanesbrands Holdco. Pursuant to the Merger Agreement, each share of the Issuer's common stock ("Hanesbrands Common Stock") reported on this Form 4 was ultimately converted into the right to receive (a) 0.102 common shares of Gildan ("Gildan Common Shares") and (b) $0.80 in cash, without interest.

Footnote F2

Pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each, a "Hanesbrands RSU"), whether vested or unvested, was ultimately converted into a Gildan restricted stock unit (each, a "Gildan RSU"). The number of Gildan Common Shares subject to each such Gildan RSU was determined by multiplying the number of shares of Hanesbrands Common Stock subject to such Hanesbrands RSU immediately prior to the First Gildan Merger Effective Time (as defined in the Merger Agreement) by the Equity Award Exchange Ratio, rounding down to the nearest whole number of Gildan Common Shares.

Footnote F3

(Continued from Footnote 2) The "Equity Award Exchange Ratio" means the sum of (a) 0.102 and (b) the quotient, rounded to two decimal places, obtained by dividing (i) $0.80 by (ii) the average of the volume weighted averages of the trading prices of Gildan Common Shares on the New York Stock Exchange on each of the 20 consecutive trading days ending on (and including) the trading day that is two trading days prior to the date on which the closing of the transactions pursuant to the Merger Agreement occurs.